Current Oncology Reports

, 16:401

Prospects and Pitfalls of Personalizing Therapies for Sarcomas: From Children, Adolescents, and Young Adults to the Elderly

Sarcomas (SR Patel, Section Editor)

DOI: 10.1007/s11912-014-0401-5

Cite this article as:
Subbiah, V. Curr Oncol Rep (2014) 16: 401. doi:10.1007/s11912-014-0401-5
Part of the following topical collections:
  1. Topical Collection on Sarcomas


Sarcomas are a heterogeneous class of tumors that affect all ages, from children, adolescents, and young adults to the elderly. Within this panoply of tumor subtypes lies the opportunity to bring to bear a vision of personalized medicine in which the fast-paced evolution from the “one gene, one test, one drug” approach to a comprehensive “panomic,” multiplex, multianalyte method coupled with advances in bioinformatics platforms can unravel the biology of this disease. The increasingly enlarging repertoire of novel agents provides innumerable prospects in precision medicine. Personalized therapy covers the entire spectrum of cancer care, from risk factor assessment through prevention, risk reduction, therapy, follow-up after therapy, and survivorship care. Challenges remain in implementing the science of precision medicine in the clinic, including providing comprehensive multidisciplinary care and overcoming regulatory and economic hurdles, which must be facilitated within the collaborative framework of academia, industry, federal regulators, and third-party payers.


SarcomaPersonalized therapyImmunotherapyTargeted therapyPrecision medicineNext-generation sequencing

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine and Division of PediatricsThe University of Texas MD Anderson Cancer CenterHoustonUSA